Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection

Filipa Caeiro Alves1, Rute Aguiar1, Pedro Pessegueiro1

  • 1Department of Nephrology, Hospital do Espirito Santo de Évora EPE, Évora, Portugal.

BMJ Case Reports
|March 19, 2018
PubMed

Insights

A rare thrombotic microangiopathy (TMA), thrombotic thrombocytopenic purpura (TTP), was diagnosed in a woman following a respiratory infection. Prompt treatment with plasmapheresis and steroids led to recovery, highlighting the importance of early diagnosis and intervention.

Area of Science:

  • Hematology
  • Nephrology
  • Infectious Disease

Background:

  • Thrombotic microangiopathy (TMA) is a serious condition involving endothelial damage and microvascular thrombosis.
  • It can lead to organ damage, particularly in the kidneys, and is characterized by low platelets and red blood cell destruction.

Observation:

  • A 36-year-old woman presented with a rash and symptoms of TMA after an upper respiratory infection.
  • Lab results confirmed TMA, including anemia, thrombocytopenia, schistocytes, and elevated LDH.
  • The patient developed antibodies against ADAMTS13, indicating acquired thrombotic thrombocytopenic purpura (TTP).

Findings:

  • The patient's TTP was triggered by a Mycoplasma pneumoniae infection.
  • Treatment with daily plasmapheresis and prednisolone resulted in a favorable clinical outcome.
  • Positive anti-ADAMTS13 antibodies confirmed the diagnosis of acquired TTP.

Implications:

  • Prompt diagnosis and treatment are critical for improving outcomes in TTP, a rare disease with high mortality.
  • Identifying infection triggers, such as Mycoplasma pneumoniae, may lead to new therapeutic or preventive strategies for TTP.
  • This case underscores the link between infections and the development of thrombotic microangiopathies.

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
929
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
3.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
830
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.6K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
908
Infection01:20

Infection

When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
12.8K